Cancer Nanomedicine: Bridging Molecular Innovation, Computation al Docking, and Clinical Translation
Abstract:
Background: While there have been tremendous advancements in the field of oncology, conventional chemo therapeutic agents remain limited by systemic toxicity, poor selectivity, and tumour heterogeneity. Nanomedi cine offers a disruptive transformation through the utilization of nanoscale drug carriers to deliver therapies in a targeted fashion, facilitate combination therapy, and allow for concurrent diagnostics.
Scope and Innovation: This review examines precision-targeting mechanisms, stimulus-responsive platforms, and new frontiers in nanotechnology in cancer therapy. Passive targeting via drug release through the en hanced permeability and retention (EPR) effect has significant underlying clinical variances, as <1% of total dose arrive at the tumor. Active targeting via immunoliposomes or ligand-functionalized nanoparticles ad dresses variation of drug delivered, and, although more effective, active-targeting also has issues with receptor population variability and logistics in manufacturing. Stimulation responsive and multimodal nanoplatforms may be initiated through pH, redox, light, or enzyme triggers, allowing release at the desired time. However, these approaches face biocompatibility and scale-up challenges.
Emerging Innovations: Biomimetic systems, such as nanoparticles coated with erythrocytes and albumin par ticles, could enhance some of the immune evasion and circulation challenges one experiences with tumor drug delivery. Metal-based nanocatalysts (i.e., ruthenium-derived oxidisers) have demonstrated efficacy against hypoxic tumours, facilitating oxygen-independent cytotoxicity.
Conclusions and Future Directions: Modular, reproducible manufacturing; companion diagnostics for pa tient stratification; predictive translational models including organoids and PDX systems; and global regula tory harmonisation are crucial in closing the gap between research and clinical translation. Future nanomed icine must also include catalytic, biomimetic, and computationally optimised designs that facilitate biological validation, manufacturability, and clinical feasibility—defining the next generation of precision cancer ther apeutics.
